Neuraxpharm

Privately held: no public share price · Spain

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Ublituximab(Briumvi)
Approved
CD20Monoclonal antibody
Multiple SclerosisSchizophreniaMyasthenia Gravis

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
January 2027 (1)
Ublituximab · BriumviPhase 3Relapsing Multiple Sclerosis
Est. primary completion 2027-01-21 · NCT05877963 · CT.gov ↗
What to watch
July 2027 (1)
Ublituximab · BriumviPhase 2Multiple Sclerosis
Est. primary completion 2027-07-31 · NCT07503873 · CT.gov ↗
What to watch
2028 (2)
July 2028 (1)
Ublituximab · BriumviPhase 2Myasthenia Gravis
Est. primary completion 2028-07-01 · NCT07673744 · CT.gov ↗
What to watch
December 2028 (1)
Ublituximab · BriumviPhase 2Schizophrenia
Est. primary completion 2028-12-12 · NCT07680946 · CT.gov ↗
What to watch
2030 (1)
January 2030 (1)
Ublituximab · BriumviPhase 2/3Relapsing Multiple Sclerosis
Est. primary completion 2030-01-01 · NCT07220252 · CT.gov ↗
What to watch
2032 (1)
May 2032 (1)
Ublituximab · BriumviPhase 3Relapsing Multiple Sclerosis (RMS)
Est. primary completion 2032-05-31 · NCT04130997 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

9 June 2026Topline resultUblituximabPhase 1 topline of subcutaneous ublituximab (BRIUMVI) in myasthenia gravis
TG THERAPEUTICS, INC. · Source ↗

Financial reports

No financial reports recorded.